Interim Report 1 January - 31 March 2023

• 53% increase in gross order intake and 56% increase in net sales compared to the corresponding quarter of the previous year
• Continued growth in user base globally and continued increase in clinical acceptance
• Distribution network established in the US

”In the first quarter of 2023, we experienced our best quarter to date in all respects, with higher sales (+56%), greater gross order intake (+53%) and more customers (+20%). On a rolling 12 months basis, the user base, i.e. the number of orthopaedic surgeons who use Episealer®, increased by 46% (105), and user base growth is of great importance to us, and thus something we work hard for. As we have said on several occasions before – we are only scratching the
surface and we feel that it is getting easier for us to get access to the large masses of orthopaedic surgeons that we want to approach. This is due to all the data and clinical experience we have now gathered, as well as the fact that our regulatory work is starting to bear fruit in earnest. Orthopaedic surgeons also continue to use our implants with the frequency we wish. Overall, we believe we are precisely taking the right step,”  says Pål Ryfors, CEO Episurf Medical.

First quarter 2023 compared to 2022, Group

» Group net sales amounted to SEK 2.5m (1.6)
» Gross order intake amounted to SEK 2.6m (1.7)
» Order book amounted to SEK 2.2m (1.5)
» Loss for the period amounted to SEK -23.2m (-16.4)
» Earnings per share amounted to SEK -0.09 (-0.06)

Significant events during the first quarter 2023
» Episealer® health economy publication was accepted for publication in Journal of ISAKOS
» The first Episealer® Knee surgery in Malaysia was planned
» The first Episealer® Talus Surgery in India was scheduled

Significant events during after the first quarter
» Episurf Medical provided update on establishment of US commercial organisation